Literature DB >> 24433411

Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.

Chiara Piana1, Meindert Danhof, Oscar Della Pasqua.   

Abstract

AIMS: The accuracy of model-based predictions often reported in paediatric research has not been thoroughly characterized. The aim of this exercise is therefore to evaluate the role of covariate distributions when a pharmacokinetic model is used for simulation purposes.
METHODS: Plasma concentrations of a hypothetical drug were simulated in a paediatric population using a pharmacokinetic model in which body weight was correlated with clearance and volume of distribution. Two subgroups of children were then selected from the overall population according to a typical study design, in which pre-specified body weight ranges (10-15 kg and 30-40 kg) were used as inclusion criteria. The simulated data sets were then analyzed using non-linear mixed effects modelling. Model performance was assessed by comparing the accuracy of AUC predictions obtained for each subgroup, based on the model derived from the overall population and by extrapolation of the model parameters across subgroups.
RESULTS: Our findings show that systemic exposure as well as pharmacokinetic parameters cannot be accurately predicted from the pharmacokinetic model obtained from a population with a different covariate range from the one explored during model building. Predictions were accurate only when a model was used for prediction in a subgroup of the initial population.
CONCLUSIONS: In contrast to current practice, the use of pharmacokinetic modelling in children should be limited to interpolations within the range of values observed during model building. Furthermore, the covariate point estimate must be kept in the model even when predictions refer to a subset different from the original population.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  covariates; model predictive power; paediatrics; simulations

Mesh:

Substances:

Year:  2014        PMID: 24433411      PMCID: PMC4168389          DOI: 10.1111/bcp.12322

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Design of pharmacokinetic studies for latent covariates.

Authors:  Chakradhar V Lagishetty; Carolyn V Coulter; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-10       Impact factor: 2.745

Review 2.  Role of modelling and simulation: a European regulatory perspective.

Authors:  Siv Jönsson; Anja Henningsson; Monica Edholm; Tomas Salmonson
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 3.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Automated covariate selection and Bayesian model averaging in population PK/PD models.

Authors:  David J Lunn
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-11-08       Impact factor: 2.745

5.  A fast method for testing covariates in population PK/PD Models.

Authors:  Akash Khandelwal; Kajsa Harling; E Niclas Jonsson; Andrew C Hooker; Mats O Karlsson
Journal:  AAPS J       Date:  2011-07-02       Impact factor: 4.009

Review 6.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

Review 7.  Statistical methods for bridging studies.

Authors:  Shein-Chung Chow; Chieh Chiang; Jen-pei Liu; Chin-Fu Hsiao
Journal:  J Biopharm Stat       Date:  2012-09       Impact factor: 1.051

8.  Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.

Authors:  Victor Musiime; Lindsay Kendall; Sabrina Bakeera-Kitaka; Wendy B Snowden; Florence Odongo; Margaret Thomason; Philippa Musoke; Kimberly Adkison; David Burger; Peter Mugyenyi; Adeodata Kekitiinwa; Diana M Gibb; A Sarah Walker
Journal:  Antivir Ther       Date:  2010

9.  A model-based approach to dose selection in early pediatric development.

Authors:  M Cella; F Gorter de Vries; D Burger; M Danhof; O Della Pasqua
Journal:  Clin Pharmacol Ther       Date:  2010-01-27       Impact factor: 6.875

Review 10.  Blood sample volumes in child health research: review of safe limits.

Authors:  Stephen R C Howie
Journal:  Bull World Health Organ       Date:  2010-09-10       Impact factor: 9.408

View more
  5 in total

1.  Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials.

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

2.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

3.  Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques.

Authors:  D Teutonico; F Musuamba; H J Maas; A Facius; S Yang; M Danhof; O Della Pasqua
Journal:  Pharm Res       Date:  2015-05-21       Impact factor: 4.200

4.  Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group.

Authors:  Athimalaipet V Ramanan; Neena Modi; Saskia N de Wildt
Journal:  Pediatr Res       Date:  2021-06-07       Impact factor: 3.953

Review 5.  How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.

Authors:  Eric Vermeulen; John N van den Anker; Oscar Della Pasqua; Kalle Hoppu; Johanna H van der Lee
Journal:  J Pharm Pharmacol       Date:  2016-09-27       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.